Meta-analysis confirms rosiglitazone's poor safety recordBMJ 2007; 335 doi: https://doi.org/10.1136/bmj.335.7620.586-b (Published 20 September 2007) Cite this as: BMJ 2007;335:586
Rosiglitazone is still approved by the US Food and Drugs Administration (FDA) for the treatment of type 2 diabetes, despite evidence from meta-analyses that it is associated with an increased risk of heart attack and heart failure⇑.
A third meta-analysis, this time …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial